Breast Carcinoma
We recommend
Adjuvant Treatment of Early Invasive HER2+ Breast Cancer − Results of the Katherine Study
Women with breast cancer found to have residual invasive disease during surgery after neoadjuvant chemotherapy and HER2-targeted therapy have a significantly worse prognosis. For these patients, the Czech Oncology Society ČLS JEP recommends adjuvant therapy with trastuzumab emtansine based on data from the Katherine clinical study. However, this treatment has not yet been covered by public health insurance, with reimbursement starting from March 1, 2021.
San Antonio: Results of Breast Cancer Treatment with Combination of Pertuzumab, Trastuzumab, and AI After 6 Years
The virtual conference dedicated to breast cancer, which took place December 8–11 in San Antonio,…
Targeted Treatment of HER2-Positive Breast Tumors – Updates from ESMO 2020 Congress
The recent European Society for Medical Oncology (ESMO) Congress took place virtually. We bring you…
Articles on this topic
Journal articles Fertility preserving methods in women with breast cancer before gonadotoxic therapy
1
2
Subscribe
Most read on this topic
- Breast cancer in elderly patients over 70 years of age
- Kadcyla in a New Indication – Adjuvant Therapy for Early HER2+ Breast Cancer
- Targeted Treatment of HER2-Positive Breast Tumors – Updates from ESMO 2020 Congress
- Adjuvant Treatment of Early Invasive HER2+ Breast Cancer − Results of the Katherine Study
- Preserving Quality of Life for Patients During Palliative Treatment of Triple-Negative Breast Cancer
- Quality of Life of Patients on Adjuvant Treatment for HER2-Positive Breast Cancer
Related topic